Trial Profile
Effect of additional single or repeated dosage of Kappaproct® to corticosteroid treated patients with brain oedema caused by brain tumour: a multicentre open one-arm non-randomised trial
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Cobitolimod (Primary)
- Indications Brain oedema
- Focus Therapeutic Use
- Acronyms Kappaproct study
- Sponsors InDex Pharmaceuticals
- 07 Feb 2017 New trial record